Details

Autor(en) / Beteiligte

• Mayo, Joseph R.
• Navran, Stephen S.
• Huzoor-Akbar
• Miller, Duane D.
• Feller, Dennis R.

Titel

Stereo-dependent inhibition of human platelet function by the optical isomers of trimetoquinol

Ist Teil von

• Biochemical pharmacology, 1981-08, Vol.30 (16), p.2237-2241

Ort / Verlag

England: Elsevier Inc

Erscheinungsjahr

1981

Quelle

Access via ScienceDirect (Elsevier)

Beschreibungen/Notizen

• The stereoisomers of trimetoquinol [1-(3',4',5'-trimethoxybenzyl)-6–7-dihydroxy-1,2,3,4-tetrahydroisoquinoline; TMQ] were shown to have potent and selective inhibitory effects on human platelet function in vitro. the R(+)-isomer was 12.1-, 12.3-, 39.2-, 82.9- and 36.0-fold more effective than the S(−)-isomer as an inhibitor of aggregation induced by arachidonic acid (AA), collagen, the epoxymethano-PGH2 analogs U44069 and U46619, and thromboxane A; (TxA 2) respectively. the concentrations of the R(+)-isomer that produced 50 percent inhibition (IC 50) of platelet aggregation were 4.2, 4.3, 1.4, 0.14 and 0.64 μM using AA, collagen, U44069, U46619, and TxA 20 as respective inducers. the graphical approximation of an inhibitory Constant ( K i = 0.13 μM) for the effect of TMQ on U46619-induced aggregation suggested that a competitive-like inhibition was operative. In other experiments, platelet aggregation and serotonin release induced by U46619 were inhibited differentially by the TMQ stereoisomers with nearly identical concentration-response curves. In addition, racemicTMQ blocked the secondary phase of platelet aggregation and serotonin release induced by ADP. These data, together with the ability of the TMQ stereoisomers to selectively inhibit TxA 2-induced aggregation, suggest that TMQ is an inhibitor of endoperoxide or TxA 2 action, e.g. a thromboxane A 2 receptor antagonist.